Objective: The aim of this study was to measure the effectiveness, safety, and use of anti-
tumor necrosis Factor (TNF) therapy in pediatric inflammatory bowel disease in the United …

The landscape of pediatric inflammatory bowel disease is rapidly evolving. The therapeutic
advances seen in the adult arena are rapidly being adopted by pediatric gastroenterologists …

Resumen NAVAS-LOPEZ, Víctor Manuel et al. Efficacy and safety of adalimumab in the
treatment of Crohn's disease in children. Rev. esp. enferm. dig.[online]. 2013, vol. 105, n. 10 …

Background: The utilization of anti-tumor necrosis factor-α (anti-TNF-α) biosimilars in
inflammatory bowel disease (IBD) is constantly increasing. However, pediatric data are …

Background Prior studies evaluating the relationship between tumor necrosis factor–alpha
inhibitors (TNFI) and infection were conducted in adults and had conflicting findings. We …

The introduction of biological agents with strong anti-inflammatory action, such as antitumor
necrosis factor (TNF) agents, has changed inflammatory bowel disease (IBD) treatment …

Background: Loss of response in pediatric inflammatory bowel disease patients treated with
biologic medications can be due to development of anti-drug antibodies. Natural history of …

Este es el primer Consenso Latinoamericano de la Pan American Crohn's and Colitis
Organisation (PANCCO) que corresponde a situaciones especiales en pacientes con …

Crohn′ s disease affects increasing numbers of children worldwide. Generally, childhood‐
onset disease runs a more severe course than in adults and has a greater impact on quality …

Abstract Background. A 17-year-old white male with Crohn's disease who was receiving
maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented …